AFTD Webinar: Genetic FTD — To Test or Not to Test

The decision to learn one’s own genetic risk for developing FTD is highly personal. An individual’s test results may reveal information not only about their own status, but may shed light on other family members’ risk for developing FTD. But many current FTD studies and clinical trials require participants with specific genes. Now more than…

Read More

AFTD and Denali Therapeutics Discuss Takeda Pharmaceuticals Partnership to Develop FTD-Focused Therapeutic

Banner graphic: AFTD 2023 Education Conference - Denali/Takeda team interview

Recently, members of the Denali Therapeutics team provided insights into their work and partnership with Takeda to develop a therapeutic to treat FTD-GRN (Frontotemporal Dementia caused by GRN gene mutation) and shared what inspires them to engage in neurodegenerative disease research.   Could you share your company’s approach to developing an FTD-focused therapeutic? Denali is…

Read More

Study Evaluates the Feasibility of ALLFTD’s Mobile App to Collect FTD Diagnostic Data

Graphic: study evaluates the feasibility of ALLFTD's mobile app to collect diagnostic data

A study published in the journal Alzheimer’s and Dementia evaluates whether a mobile app developed by the multi-site FTD research consortium ALLFTD can help users record and transmit scientifically acceptable diagnostic data for FTD. FTD’s symptoms can make travel to medical and research facilities difficult, especially for those who live in remote, rural areas. This…

Read More

Living Well with PPA

“Living Well with PPA” is a six-week online support program designed to provide a safe space so that people newly diagnosed with primary progressive aphasia can cope with their diagnosis together. Each interactive one-hour session will provide an outlet to learn and find support with others in the same situation. Participants will: Learn more about…

Read More

Advocacy Update: AFTD Ambassadors Offer Insights at July NAPA Meeting

Graphic: Advocacy Update - AFTD Ambassadors Offer Insights at July NAPA Meeting

At the most recent meeting of the National Alzheimer’s Project Act (NAPA) Advisory Council, AFTD Ambassadors Katie Zenger and Terry Walter shared their experiences to help educate federal officials on the needs and concerns of people affected by FTD. NAPA was passed in 2011 to address the needs of families affected by dementia and to bring coordination and focus…

Read More

AFTD Educational Webinar — Genetic FTD: To Test or Not to Test

Tuesday, August 15 3 – 4 p.m. ET The decision to learn one’s own genetic risk for developing FTD is highly personal. An individual’s test results may reveal information not only about their own status, but may shed light on other family members’ risk for developing FTD. But many current FTD studies and clinical trials…

Read More

AFTD Educational Webinar — Genetic FTD: To Test or Not to Test

The decision to learn one’s own genetic risk for developing FTD is highly personal. An individual’s test results may reveal information not only about their own status, but may shed light on other family members’ risk for developing FTD. But many current FTD studies and clinical trials require participants with specific genes. Now more than…

Read More